Multimodal Rehabilitation on Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy

Gastric Cancer Clinical Trial

Official title:

The Impact of Multimodal Rehabilitation on the Outcomes of Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy: A Phase II, Multicenter, Open Label, and Randomized Clinical Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06419140
• Other study ID #: IRB-2024-349
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 1, 2024
• Est. completion date: December 31, 2025

Study information

• Verified date: May 2024
• Source: Zhejiang Cancer Hospital
• Contact: Jieer Jieer, Dr
• Phone: 0571-88122062
• Email: jieerying[@]aliyun.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study has established a multidisciplinary rehabilitation team to recruit patients who underwent radical D2 gastrectomy in multiple centers and divided them into a rehabilitation group and a control group. Intervention will be carried out every time the patients come to the hospital for adjuvant chemotherapy and review. The control group uses traditional intervention model, and the rehabilitation group uses combined exercise/nutrition/psychology rehabilitation intervention.

This study is expected to promote early recovery after gastric cancer surgery through multidisciplinary rehabilitation intervention, reduce the occurrence of complications, improve patients' tolerance to adjuvant chemotherapy, and improve patients' quality of life, and hope to improve the short-term and long-term outcomes of gastric cancer patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 138
• Est. completion date: December 31, 2025
• Est. primary completion date: May 1, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Clinical diagnosis of Alzheimer's Disease

• Must be able to swallow tablets

• Age 18 to 75 years old

• Patients with gastric adenocarcinoma (including gastroesophageal junction adenocarcinoma) confirmed by histopathology to be in pathological stage II/III (based on the eighth edition of the AJCC Cancer Staging Manual)

• The patient underwent D2 radical resection within 3-6 weeks before randomization; and met the R0 resection criteria

• The patient can undergo postoperative adjuvant chemotherapy after being selected into the randomization group, and the regimen is SOX/XELOX

• Have not received previous anti-tumor treatment (including systemic chemotherapy and local radiotherapy), except for initial gastrectomy of the primary lesion

• ECOG status score 0 or 1, with physical conditions to participate in sports training?Have sufficient bone marrow reserve function, ANC =1.5×109/L, platelet count =75×109/L, Hb =90 g/L before enrollment, and no bleeding tendency

• Liver function test: alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) are all = 2.5×ULN; serum bilirubin = 1.5×ULN. For patients known to have Gilbert's disease: Serum bilirubin level = 3xULN

• Renal function test: Serum creatinine (Cr) = 1.5 x ULN or creatinine clearance > 50 ml/min (calculated according to Cockroft-Gault)

• No mental illness, speech disorder or consciousness disorder, have certain understanding, communication and reading abilities, and be able to complete the questionnaire independently or with the assistance of the researcher

• During the study, at least one source of social support (family member or friend) can monitor the safety and compliance of the intervention program

• Can understand the situation of this study, and the patient and/or legal representative voluntarily agree to participate in this trial and sign the informed consent form.

Exclusion Criteria:

• Receive neoadjuvant chemotherapy or radiotherapy before surgery;

• Participate in other clinical trials related to health behavior within 3 months before the trial;

• Treated with any other study drugs or participated in another clinical trial with therapeutic intent within 28 days before enrollment;

• Uncontrolled serious medical illness that the investigator believes will affect the subject's acceptance of the rehabilitation program, such as combined serious medical illness, including severe heart disease (such as New York Heart Association (NYHA) Class II or worse congestion heart failure), cerebrovascular disease, uncontrolled diabetes, uncontrolled hypertension, uncontrolled infection, etc.;

• Lack of ability to participate in sports training (such as: disability, paralysis of lower limbs, etc.); not suitable for participating in sports training, such as those suffering from skeletal muscle diseases, fractures within 6 months; suffering from exercise contraindications (angina pectoris, within 6 months) Myocardial infarction, congestive heart failure, chronic obstructive pulmonary disease, planned hip or knee replacement, use of a walker or wheelchair, recent stroke with hemiplegia, etc.);

• Those who are receiving other forms of nutritional intervention; those who refuse to use oral nutritional preparations;

• There is uncontrolled mental illness;

• Known active HIV, HBV and HCV infection;

• Patients with malignant tumors other than gastric cancer (except current gastric cancer) within the past 5 years; are eligible if they meet all the following criteria: treatment of malignant tumors with the purpose of cure, such as fully treated cervical cancer in situ, non-melanoma skin Cancer, localized prostate cancer after radical resection (PSA = 10ng/ml); at the same time, no signs of recurrence or metastasis were found based on imaging follow-up results and any disease-specific tumor markers;

• Those with difficulty swallowing, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, or perforation;

• Pregnant or lactating female patients, or subjects of childbearing age who refuse to take contraceptive measures;

• Patients judged by the researcher to be unfit to participate in this study.

Related Conditions & MeSH terms

• Adenocarcinoma
• Gastric Cancer

Intervention

Drug:
• Standard SOX/XELOX adjuvant chemotherapy plus multimodal rehabilitation
Motivational counseling to perform nutritional, psychological, and exercise inventions

Locations

Country	Name	City	State
China	Zhejiang Cancer Hospital	Hangzhou	Zhejiang

Sponsors (1)

Lead Sponsor	Collaborator
Zhejiang Cancer Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adjuvant chemotherapy completion rate	Completion rate of 8 cycles of adjuvant chemotherapy	At the end of Cycle 8 (each cycle is 21 days)
Secondary	3-year disease-free survival (DFS)	Proportion of subjects who have been free of disease recurrence within 3 years from randomization.	3 year
Secondary	Overall survival	Time from randomization to death	3 year
Secondary	Emotional state	Measured by GAD-7 questionnaire	2 year
Secondary	Weight	Weight	through study completion, an average of 2 year
Secondary	Adverse event	Adverse event were evaluated through CTCAE	At the end of Cycle 8 (each cycle is 21 days)